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Abstract
Obstructive sleep apnea (OSA) significantly impacts cardiovascular health, demonstrated by 
observational investigations showing an independently increased risk of ischemic heart disease, 
diabetes, hypertension, congestive heart failure, acute coronary syndrome, stroke, cardiovascular 
mortality, and all-cause mortality. Positive airway pressure (PAP), a medical therapy for sleep 
apnea, reverses airway obstruction and may help reduce cardiovascular risk. Prior to planning 
large Phase III randomized controlled trials to test the impact of PAP on cardiovascular outcomes, 
several gaps in knowledge need to be addressed. This paper describes two independent studies that 
worked collaboratively to fill these gaps. The populations, design features, and relative benefits/
challenges of the two studies (SleepTight and BestAIR) are described. Both studies were 
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encouraged to have multidisciplinary teams with expertise in behavioral interventions to improve 
PAP compliance. Both studies provide key information that will be useful to the research 
community in future large-scale, event-driven, randomized trials to evaluate the efficacy and/or 
effectiveness of strategies to identify and treat significant obstructive sleep apnea for decreasing 
risk of major adverse cardiovascular events in high-risk patients.
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BACKGROUND
Obstructive sleep apnea (OSA) is common in the general population. Prevalence rates of 
mild to moderate OSA of about 15% are reported; and approximately 4 to 5% of the 
population is classified as having severe OSA.1-3 Among patients at risk for or with 
established cardiovascular disease (CVD), OSA prevalence rates are even greater.4, 5 
Untreated OSA in the US is estimated to contribute $3B in medical costs related to greater 
health care utilization.6-8 In particular, OSA significantly impacts cardiovascular health, 
demonstrated by observational investigations showing an independently increased risk of 
ischemic heart disease, diabetes, hypertension, congestive heart failure, acute coronary 
syndrome, stroke, cardiovascular mortality, and all-cause mortality.9-13 Mechanistic studies 
suggest several plausible biologic mechanisms for this risk, including recurrent hypoxia, 
frequent arousal from sleep, intrathoracic pressure changes, vascular inflammation, 
autonomic activation, and metabolic dysregulation.14
Positive airway pressure (PAP) reverses airway obstruction and may represent and important 
treatment to reduce cardiovascular risk. However, essential information is needed prior to 
conducting a large Phase III trial to directly address gaps in knowledge regarding the impact 
of PAP on cardiovascular risk. For example, whereas short-term studies suggest that 
increased duration of effective CPAP use may translate into greater vascular risk 
reduction,15 more research is warranted to determine both key strategies for improving 
CPAP adherence over the long-term, and whether there is a minimal dose of PAP needed to 
alter vascular risk. This need is especially true of high risk vascular populations, and 
enrollees in clinical trials in research settings, who may be less sleepy than patients referred 
through sleep- related clinical pathways. Additionally, design considerations regarding 
equipoise and the selection of appropriate control groups as well as the feasibility of 
recruitment, randomization, and retention of study populations must also be addressed. 
Information about effect size of PAP therapy is also required, and can be inferred by 
corresponding changes in pathophysiologic markers of cardiovascular and cerebrovascular 
disease.
In response to these needs, the National Heart, Lung and Blood Institute (NHLBI) at the 
National Institutes of Health (NIH) released a Request for Applications (RFA) on “Reducing 
Cardiovascular Disease Risk Through Treatment of Obstructive Sleep Apnea (U34)” (RFA-
HL-10-023) to 1) encourage research to establish the feasibility of conducting long-term 
PAP treatment in research settings among individuals with increased cardiovascular risk 
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profiles, 2) evaluate the potential for such treatment to produce changes in cardiovascular 
disease risk profiles, 3) identify feasibility of study design strategies for future event-driven 
Phase III trials, and 4) include multidisciplinary teams with expertise in behavioral 
interventions to improve PAP compliance. An additional stipulation of this mechanism was 
that research activities were to be coordinated through a Joint Steering Committee process 
that would facilitate developing and reporting standardized measures of key common 
variables, such as population characteristics and entry criteria, PAP adherence, key protocol 
characteristics, and common biological outcomes, to facilitate comparison of study 
outcomes. The request was for three-year randomized controlled trial (RCT) planning grants 
that focused on PAP treatment, for the purpose of conducting preliminary studies that could 
guide the research community in the design of Phase III clinical trials to test whether PAP 
treatment of OSA reduces vascular events. The alternative populations, design features, and 
relative benefits/challenges of the two studies funded under this mechanism (Sleep Tight- 
U34HL105285 and BestAIR-U34HL105277) are described below. The authors of this paper 
are solely responsible for the design and conduct of the respective studies, the drafting and 
editing of this manuscript and its final content.
SLEEPTIGHT
Overall Trial Design
The “Sleep Apnea in TIA: Reducing Cardiovascular Risk with Positive Airway Pressure” 
(SleepTight) study is a prospective, randomized controlled planning trial among patients 
with transient ischemic attack (TIA) and ischemic stroke, comparing the effectiveness of 
strategies for the diagnosis and treatment of sleep apnea with usual care, over 12 months at 
centers in Connecticut and Indiana (Table I, Figure 1). The eligibility criteria are specified in 
Table II. The target population was selected because of their high prevalence of obstructive 
sleep apnea (60-80%),4, 16 and their heightened risk for recurrent cerebrovascular and 
cardiovascular events despite current prevention strategies.
255 patients with TIA or stroke are randomly assigned using a 1:1:1 (control:standard PAP: 
enhanced PAP) randomization scheme to either usual care or a home-based diagnosis and 
treatment approach that includes ambulatory polysomnography and initiation of PAP for 
patients with sleep apnea (Figure 1). Control patients could undergo diagnosis and treatment 
of sleep apnea if suspected as part of usual clinical care. The randomization is stratified by 
center (Connecticut or Indiana) and neurologic event type (TIA or stroke). Intervention 
patients with sleep apnea receive either a standard PAP treatment intervention or an 
enhanced protocol designed to increase long-term PAP adherence.
The primary aims consist of seeking to evaluate: whether the intervention results in 
significant reductions in several markers of cardiovascular risk; the optimal adherence levels 
to achieve these improvements; and whether an enhanced intervention protocol results in 
improved long-term PAP adherence rates. The secondary aims are to collect cerebrovascular 
and cardiovascular event rates as pilot data for a potential future event-driven trial. Patients 
are recruited in the acute hospital environment, but the major setting of the study is the 
patient's home. This setting was intended to facilitate the participation of an acute TIA/
stroke population with limited mobility and competing demands.
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Baseline Assessments
Data collected at baseline include demographics, co-morbidities, medications (using the 
WHO classification), blood pressure, heart rate, and anthropometrics. The ABCD2 score, a 
system used to predict short-term recurrent event rates among patients with TIA, and the 
NIH Stroke Severity (NIHSS) score, are also calculated. Patients are interviewed to 
complete measures of self-efficacy in sleep apnea, sleepiness, sleep duration, functional 
status, and mood. Physiologic measurements include unattended full polysomnography, 24-
hour holter monitoring, 24-hour ambulatory blood pressure, phlebotomy, flow-mediated 
vasodilation, and carotid doppler ultrasonography (Table III).
Study Interventions
Polysomnography is performed using the Safiro™ type 2 sleep monitor (Compumedics, 
Victoria Australia). Scoring conforms to standards of the American Academy of Sleep 
Medicine (AASM); hypopneas are scored using the AASM alternative definition of (≥3% 
oxygen desaturation or arousal).17 Patients with an apnea hypopnea index (AHI) of ≥ 5 
events/hour are diagnosed as having sleep apnea and are initiated on auto-pap titration 
protocols using the System One® PAP device (Phillips Respironics).
The Standard Intervention is intended to approximate “real world” PAP support, and 
consists of three in-person contacts and telephone contacts throughout the 12-month follow-
up period. The initial in-person contact focuses on providing the results of the diagnostic 
sleep study and instruction regarding PAP equipment. The second and third in-person 
contacts occur at one and three months, respectively, allowing for interrogation of the PAP 
unit for adherence data questioning regarding symptom improvement, trouble shooting, and 
encouragement of continued PAP use. Interim regular telephone contact is made to inquire 
regarding adverse events. A final visit occurs at one year for outcome assessment.
The Enhanced Intervention adds three components: (1) targeted education, (2) behavioral 
adherence intervention, and (3) increased PAP support. The intervention protocol is based 
on the conceptual frameworks of the narrative model18 and self-determination theory,19, 20 
and consists of intensive in-person patient contact during the first month of PAP treatment, 
with subsequent follow-up telephone/in-person contact for continuing support. These data 
are used to identify potential barriers and facilitators of PAP use. A video for participant 
viewing was developed (for use by both studies) that features a real-life role model who 
demonstrates ambivalence around PAP use and the resolution of this ambivalence- resulting 
in enhanced motivation and efforts adhere to PAP, successful problem solving, increased 
confidence, and ultimately PAP adherence. Starting within the first week and then weekly 
for the first month, the focus is on adherence interventions designed to “link” PAP use to 
intrinsically motivating factors of the patient. Subsequently, the patient receives monthly 
phone contacts, with an in-person contact at 3 and 6 months to serve as “booster sessions” 
for the targeted education and behavioral adherence intervention. A final visit takes place at 
12 months for outcomes assessment.
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Outcomes
The outcomes in SleepTight were based on biologically plausible mechanisms by which 
OSA may lead to cardiovascular risk. These pathways include intermittent hypoxia, 
heightened sympathetic activity, inflammation, metabolic dysregulation, leading 
downstream to endothelial injury, and atherosclerosis.
Endpoints include change (baseline to follow-up) in markers of inflammation, autonomic 
activity, insulin resistance, flow mediated vasodilation, and carotid intima-media thickness 
(Table III). The primary comparison is an intention-to-treat analysis of changes in vascular 
disease biomarkers between patients enrolled in the two intervention groups versus those 
enrolled in the control group. Given that only patients with sleep apnea in the intervention 
groups will receive CPAP, the initial power calculation was based on an estimated 
prevalence of sleep apnea of 60%21,22 and a retention rate at one-year follow-up of 0.90. 
The power calculation was based on a method by Hedeker et al.23 A sample size of 255 
provided at least 80% power for each of the primary aims. Although patients are un-blinded, 
key investigators ascertaining outcomes remain blinded.
BESTAIR
Overall trial Design
The “Best Apnea Intervention in Research” (BestAIR) trial (Table I, Figure 2) is a planning 
study to evaluate the merits of alternative study design features for later, large-scale, Phase 3 
RCTs that address the role of sleep apnea treatment on reducing CVD morbidity. The study 
design is a 12-month parallel, randomized, double-blind, multicenter Phase-2 efficacy trial, 
with 24-hour systolic blood pressure as the primary physiological endpoint and a number of 
process measures as secondary outcomes. The study was designed to enroll 225 patients 
with moderate to severe sleep apnea (AHI >15), and with CVD risk factors or established 
CVD, whose treating physician had clinical equipoise, into a two week run-in period, and 
then to randomize an estimated 80% (n=180) of these participants into a 12-month, 4-arm 
intervention study. The run-in trial requires participants to apply nasal dilator strips (Breathe 
Right®), and a PAP mask nightly (open to the atmosphere), and complete a sleep diary. 
After demonstration of adherence with these procedures, patients are invited to a baseline 
visit at a clinical research center and subsequently randomized. Participants are then 
followed by phone and interim visits (at 6 and 12 months) until study completion. The 
eligibility criteria for the trial are specified in Table II.
Baseline Assessments
Baseline visits are conducted in the morning, following an overnight fast where urine and 
venous blood samples are obtained. Other measurements include ambulatory 24h blood 
pressure monitoring, radial artery tonometry (to assess arterial stiffness and pulse wave 
velocity), resting 12-lead electrocardiogram and 2-D echocardiography, and questionnaires 
on medical history, lifestyle, and sleep habits.
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Study Interventions
The study includes four groups: (1) Conservative Medical Therapy (CMT) alone; (2) CMT 
plus sham PAP delivered by a trained sleep technician; (3) CMT plus active PAP delivered 
by a trained sleep technician; and (4) CMT plus active PAP enhanced through behavioral 
support provided a psychologist providing a standardized PAP behavioral promotion 
intervention. Groups 1 and 2 are considered alternative control conditions and groups 3 and 
4 are considered alternative active treatments. The primary physiological, various process 
measures, and other clinical endpoints will be compared for groups 1 and 2, vs. groups 3 and 
4.
CMT—The participant is instructed on sleep hygiene, including specific techniques to 
reduce apnea, as well as healthy lifestyle guidelines. In addition, participants are provided a 
supply of nasal dilator strips to use nightly.
Active PAP and Sham-PAP Arms—In addition to receiving CMT, participants 
randomized to sham or active-PAP interventions meet with a trained sleep technician. PAP 
levels are determined through overnight laboratory titrations or through auto-PAP titration 
protocols. The core intervention delivered by the sleep technician includes education on 
PAP and mask use, information on side effects, and feedback on PAP use based on 
adherence data available through wireless tele-monitoring. Participants are scheduled to 
meet with the sleep technician at set-up, and again one week after initiating PAP, to 
reinforce PAP use and make any adjustments in the mask or pressure setting. Thereafter, the 
sleep technician meets with the participant in-person at months 1, 3, 6, and 9, using the 
available data from the PAP monitor on PAP use, mask leak, and residual AHI, to assist 
with troubleshooting.
Participants randomized to active PAP with enhanced behavioral support receive the sleep 
technician-delivered intervention described above plus a specific behavioral protocol. 
Participants speak with the behavioral interventionist 6 times, through phone or other 
contact, at weeks 3, 4, 8, 12, and 32 after beginning PAP. This strategy allows mechanical 
issues related to PAP to be addressed early (by the sleep technician), while timing the 
delivery of the behavioral intervention to times after the patient has had a chance to 
experience PAP. The enhanced intervention is based on social cognitive theory and feedback 
concerning adherence, with targeted problem solving-training. The motivational 
enhancement intervention is adapted from the motivational enhancement treatment protocol 
for PAP adherence (ME-PAP) developed by Aloia et al.24-27
Outcomes
The primary physiological outcome (see Table III) is an intermediate marker of CVD risk: 
change in 24-hour mean systolic blood pressure, measured at 6 and 12 months following 
randomization. A broader set of intermediate markers of CVD and patient-reported 
outcomes are also identified as secondary outcomes. The primary process measures are 
recruitment yields, crossover rates, retention rates, and adherence. Adherence in both PAP 
arms will be assessed through electronic wireless downloads. CMT adherence will be 
measured by responses obtained at the quarterly follow-up visits, summarizing self-reported 
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use of nasal dilators. Adjudication of clinical endpoints occurs through review of medical 
records and other data.
COMMON FEATURES AND KEY DIFFERENCES
The investigative teams collaborated throughout the duration of the projects to ensure 
several key common features between studies (Table IV), both studies use two active PAP 
intervention groups with more-versus-less intensive adherence approaches, as well as similar 
behavioral adherence approaches in the more intensive adherence protocols. Definitions, 
endpoints, trial administrative procedures, and tools are harmonized, where possible, 
between the two studies. Identical sleep study scoring procedures are used. Considerable 
overlap also exists among selected intermediate measures of cardiovascular risk, including 
inflammatory markers, insulin/glucose homeostasis, lipids, BNP, and heart rate variability. 
Both studies have identical definitions and assessment of vascular outcomes. There are 
several patient reported outcomes common to both studies, including the Epworth 
Sleepiness Scale, PHQ depression scale, and the Self Efficacy Measure for Sleep Apnea 
(SEMSA). Both studies utilize identical PAP adherence measures. Both studies utilize 
blinded ascertainment of outcomes. These efforts at harmonization are aimed to enhance 
comparability across the two studies and foster future joint analyses.
Important differences between the two studies (Table V) are also noteworthy. SleepTight 
targets high risk patients with TIA/stroke in the acute hospital setting, with follow-up in the 
home. The SleepTight study does not involve patients who have been diagnosed with sleep 
apnea (and may be symptomatic) to a control group that does not receive PAP. It is strategy-
based, randomizes prior to polysomnography, and compares the effectiveness of a diagnosis 
and treatment approach for sleep apnea versus usual care. Usual care patients may undergo 
diagnostic testing treatment for sleep apnea post-stroke/TIA, however in our experience this 
is rare<5%). This approach addresses potential ethical and safety considerations regarding 
randomizing symptomatic or high risk patients over the long-term to a control arm that does 
not include active PAP treatment. By treating soon after an acute event, the risk of recurrent 
event is high, which may decrease the total sample size required to power a study, and may 
result in a lower number needed to treat/number needed to harm (NNT/NNH). By 
randomizing to testing vs. no testing, SleepTight addresses a clinical question facing stroke 
patients and their clinicians. It asks the question: Does a strategy of polysomnography and 
PAP treatment, if indicated by at least mild OSA, reduce vascular risk in an acute post-
stroke/TIA population?
In contrast, BestAIR targets patients who have lower CV event risk profiles who are 
indetified through outpatient clinic settings, is treatment-based, randomizes after 
polysomnography, and examines the efficacy of CPAP, sham CPAP, or CMT on 
cardiovascular risk. BestAIR evaluates the safety and utility of sham CPAP and CMT 
control regimens. This approach preserves double blinding (in one arm), and addresses 
safety issues through close monitoring of adverse events and excluding severely 
symptomatic patients. By randomizing stable CVD patients and those with CVD risk 
factors, a larger sample size is required, but this focus has the potential to generalize to a 
larger group of patients. By randomizing after a positive sleep study and run-in, it focuses on 
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the physiological effect of PAP treatment. It asks the question: Does treatment with PAP 
reduce risk among patients with at least moderate OSA and either established CVD or CV 
risk factors.
Overall, both studies will inform the research community regarding key information relevant 
to the planning of future large-scale, event-driven, randomized trials to evaluate the efficacy 
or effectiveness of treating significant obstructive sleep apnea to decrease major adverse 
CVD events in high-risk patients. More generally, given the growing interest in pragmatic 
trials, the alternative use of effectiveness and efficacy in these two studies will provide 
opportunities to consider the impact of major design differences on study implementation, 
efficiency, outcomes, features, and generalizability.
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Figure 1. 
SleepTight Study Design
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Figure 2. 
BestAIR Study Design
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Table I
Key Design Features of Each Study
SleepTight (NCT01446913) BestAIR (NCT01261390)
Grantee Institutions Yale School of Medicine; Indiana School of 
Medicine
Brigham and Women's Hospital; Beth Israel Deaconess 
Medical Center
Target Population Patients with recent (within 1 week) TIA or 
ischemic stroke
Patients with established CVD; diabetes; or 3+ CVD risk 
factors; free of an acute cardiac event for prior 4 months
Overall Design Phase 2 randomized controlled trial
Recruitment Site Hospital, all follow-up occurs in patient's home Outpatient (sleep, cardiac clinics)
Run-In None 2 weeks of wearing a PAP mask open to the room
Sleep Apnea Entry Criteria AHI ≥5 events/hour AHI ≥15 events/hour
Primary Outcomes Change in five domains of cardiovascular risk 
markers (inflammatory, autonomic, metabolic, 
endothelial, and atherosclerotic)
24-hour mean systolic BP at 6 and 12 months
Secondary Outcomes Combined endpoint of 1-year vascular events or 
death rate
Arterial stiffness; cardiac function and structure 
(echocardiography); biochemical markers of glucose 
control; lipid levels, inflammation
Process Outcomes PAP adherence; recruitment yie ds; cross-over rates; retention rates, sleep apnea prevalence
Patient Reported Outcomes Stroke severity; functional status; sleepiness; mood, 
self-efficacy
Generic and sleep specific quality of life; sleepiness; 
mood; self-efficacy
Active Interventions Auto-titrating PAP (Standard vs. Enhanced Intervention)
Control Usual Care Sham-PAP; Nasal Dilator Strips, sleep education
CVD=cardiovascular disease; TIA=transient ischemic attack; AHI=apnea hypopnea index; BP=blood pressure; PAP=positive airway pressure
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Table II
Eligibility Criteria
SleepTight BestAIR
Inclusion 18 years or older 45-75 years or older (or 55-75 if without established CVD)
TIA/ischemic stroke within 1 week of symptom 
onset
Diagnosed with moderate to severe OSA (AHI ≥ 15 events/hr)
Brain imaging within 48 hours of symptoms onset Either: Established CVD; Diabetes; or Three or more established CVD 
risk factors
Exclusion Known sleep apnea Working as professional driver
Suspected sleep-disorder other than sleep apnea Diagnosed heart failure with EF of <35% or NYHA class 3 or 4 status
Hospice or patients receiving comfort measures only Less than 4 months since MI, stroke, revascularization procedure
Patients unable to use either a nasal or face mask Poorly controlled hypertension (>170/>100)
Patients who require mechanical ventilation Prior stroke with functional impairment
Non-English language patients Severe uncontrolled medical problems or medications that may influence 
study exams
Inability to provide informed consent Resting oxygen saturation <90% or nocturnal oxygen saturation <85% 
for >10%
Active suicidal ideation Prior use of prescribed PAP for sleep apnea
Lives outside the recruitment area Report of inability to spend ≥6 hours in bed
Provider does not allow research staff to contact the 
patient
Severe sleepiness defined by an Epworth Sleepiness Score of >14 or 
report of trouble staying awake while driving in the past 2 years
Low risk of having sleep apnea defined by a Berlin Score of <2
Central sleep apnea, with >50% of respiratory events classified as central 
apneas
Refusal to consider PAP use after an initial split-night PAP study (pre-
randomization)
Concurrent involvement in another research study that will result in a 
conflict determined by study doctors
OSA= obstructive sleep apnea; CVD=cardiovascular disease; TIA=transient ischemic attack; AHI=apnea hypopnea index; BP=blood pressure; 
PAP=positive airway pressure
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Table III
Outcomes
SleepTight BestAir
Physiologic Endpoints Inflammation Primary Endpoint
    High sensitivity CRP     24h SBP
    IL-6 Secondary Endpoints
Autonomic Blood Pressure Profile
    Plasma catecholamines     Nocturnal BP
    Heart rate variability     Mean 24h BP
    24hr ambulatory BP     BP dipping status
Insulin resistance Inflammation
    HOMA-IR     CRP
    HbA1c     IL-6
Atrial pressure     Fibrinogen
    BNP     PAI-1
Endothelial Injury     MRP 8-14
    Flow-mediated vasodilation Vascular Stiffness
Atherosclerosis     Augmentation Index
    Carotid intima-media thickness     Pulse Wave Velocity
Cardiac Function/Morphology
NT pro BNP
Renal function
    Urinary albumin/creatine
Dyslipidemia/Metabolism
    Total LDL and HDL
    Triglyceride
    Fasting insulin/glucose
SEMSA SEMSA
ESS ESS
Modified Rankin Scale SAQLI
NIHSS MOS-SF36
ABCD2 PHQ-8
Sleep duration
Concomitant medical care
Process Measures Recruitment rates Recruitment rates
Retention rates Retention rates
Safety Safety
Sleep Apnea Prevalence PAP Adherence
PAP Adherence Cross-Over rates
Run-in rates
Am Heart J. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Yaggi et al. Page 15
SleepTight BestAir
Cardiovascular Outcome Events Stroke, TIA, Acute coronary syndrome, Hospitalization for congestive heart failure, Death (CV or non-CV)
CVD=cardiovascular disease; TIA=transient ischemic attack; AHI=apnea hypopnea index; SBP=systolic blood pressure; PAP=positive airway 
pressure
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Table IV
Common Elements of the SleepTight and BestAIR
Study Leadership Multi-PI model: sleep and cardio/cerebrovascular expertise
Exclusion Criteria Known sleep apnea/prior PAP use
Co-morbid sleep disorder
Target population Established cardiovascular disease
Measurements 24-hour mean systolic blood pressure
Lipid profiles, glucose, insulin
CRP, IL-6, Pro-BNP
Epworth Sleepiness Score, PHQ-9
Self Efficacy Measure of Sleep Apnea
PAP Adherence hours of use
WHO Classification of Medication Use
AHI scored in same center with same scoring criteria
Clinical Endpoints Use common adjudication procedure
Active Interventions PAP
Behavioral support with enhanced education and motivation
Both direct and phone contact support
Common patient role-model video
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Table V
Distinct Features of Each Study
SleepTight BestAIR
Type of Study Effectiveness study Efficacy study
Intervention Strategy-based Treatment-based
Randomization Randomization to screen and treat vs usual care Active PAP vs no PAP
Target Population Acute stroke/TIA Established CVD or high risk, no recent acute event
Recruitment Large inpatient population; setting of acute stroke 
centers is optimal.
Large outpatient program following patients with 
established cardiovascular disease and CVD risk 
factors
Risk Level of Patients By randomizing soon after an acute CVD, the risk 
of recurrent event is high. This decreases the total 
sample size required to power a study and may 
result in lower NNT/NNH
By randomizing stable CVD patients and those with 
CVD risk factors, a larger sample size is required, 
but may benefit a larger group of patients.
Sleep Apnea Severity OSA may or may not be present (randomization pre-
polysomnography); AHI ≥ 5
OSA present (randomization post-
polysomnography); ESS ≤ 14; no drowsy driving; 
AHI ≥15
Timing of Randomization By randomizing to testing vs. no testing, addresses 
clinical question facing stroke patients and their 
clinicians
By randomizing after (+) sleep study and run-in, 
addresses the biological effect of PAP treatment
Question addressed: Does a strategy of polysomnography and PAP 
treatment, if indicated by at least mild OSA, reduce 
risk in an acute post-stroke/TIA population
Does treatment with PAP reduce risk among patients 
with at least moderate OSA and either established 
CVD or CV risk factors
Control Conditions Usual Care (unblinded) One control group (sham PAP) blinded, but assesses 
potential impact on retention in an unblinded control 
group as well
In-home vs In-clinic follow-up Burden on study staff Burden on study participant
CVD=cardiovascular disease; TIA=transient ischemic attack; AHI=apnea hypopnea index; BP=blood pressure; PAP=positive airway pressure; 
NNT=number needed to treat;NNH=number needed to harm
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